Arcadia Biosciences 3Q 2026: Revenue $1.62M, EPS $0.29 — 10-Q Summary
Arcadia Biosciences reported 3Q 2026 revenue of $1.62M, up 24% YoY, and net income of $1.76M, up 105% YoY. EPS was $0.29, down 53.2% YoY. The company cited strong product volumes and a $2.6M gain from warrant and option liabilities. Costs fell 14% due to a $175K tariff refund. Arcadia expressed doubt about its ability to continue as a going concern.
How this was made

The 30-second read
Why it matters
The earnings miss and liquidity warning are likely to depress the stock in the short term, especially given the micro‑cap nature of the company.
Market read
Primary earnings disclosure for a micro‑cap biotech; new data but limited market breadth.
What to watch
Potential upcoming partnership or licensing deals not disclosed in the filing could mitigate cash concerns.
Background
Arcadia Biosciences filed its Q3 2026 10‑Q, showing modest revenue growth but a sharp earnings decline and a going‑concern warning.
Ticker impact
Arcadia Biosciences reported Q3 2026 revenue of $1.62M and a 53% EPS decline, highlighting cash‑flow concerns and a going‑concern warning.
likely downward pressure as investors price in weaker earnings and liquidity risk
Revenue grew modestly while EPS fell sharply and the company warned of insufficient cash for the next year, a negative catalyst for a micro‑cap.
Market effects
Limited impact on the broader biotech sector; micro‑cap earnings often remain isolated.
Primarily affects U.S. small‑cap investors; no broader regional effect.
Low global relevance due to the company's small size and niche market.
Counterpoint
If the cash‑flow warning is overstated, the stock could rebound on short‑covering.
Key entities
- companyArcadia Biosciences, Inc.
Biotech firm reporting Q3 2026 results (ticker RKDA).
